One Step Into the Future: New iPSC Tools to Advance Research in Parkinson's Disease and Neurological Disorders
- PMID: 30741685
- PMCID: PMC6597965
- DOI: 10.3233/JPD-181515
One Step Into the Future: New iPSC Tools to Advance Research in Parkinson's Disease and Neurological Disorders
Abstract
Studying Parkinson's disease (PD) in the laboratory presents many challenges, the main one being the limited availability of human cells and tissue from affected individuals. As PD is characterized by a loss of dopaminergic (DA) neurons in the brain, it is nearly impossible for researchers to access and extract these cells from living patients. Thus, in the past PD research has focused on the use of patients' post-mortem tissues, animal models, or immortalized cell lines to dissect cellular pathways of interest. While these strategies deepened our knowledge of pathological mechanisms in PD, they failed to faithfully capture key mechanisms at play in the human brain. The emergence of induced pluripotent stem cell (iPSC) technology is revolutionizing PD research, as it allows for the differentiation and growth of human DA neurons in vitro, holding immense potential not only for modelling PD, but also for identifying novel therapies. However, to reproduce the complexity of the brain's environment, researchers are recognizing the need to further develop and refine iPSC-based tools. In this review, we provide an overview of different systems now available for the study of PD, with a particular emphasis on the potential and limitations of iPSC as research tools to generate more relevant models of PD pathophysiology and advance the drug discovery process.
Keywords: CRISPR; Parkinson’s disease; Stem cells; cell therapy; co-cultures; neuronal organoids.
Conflict of interest statement
The authors have no conflict of interest to report.
Figures

Similar articles
-
From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson's Disease Modeling and Regenerative Therapy.Int J Mol Sci. 2023 Jan 28;24(3):2523. doi: 10.3390/ijms24032523. Int J Mol Sci. 2023. PMID: 36768843 Free PMC article. Review.
-
CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons.Sci Rep. 2019 May 2;9(1):6811. doi: 10.1038/s41598-019-43080-2. Sci Rep. 2019. PMID: 31048719 Free PMC article.
-
Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery.Expert Opin Drug Discov. 2020 Apr;15(4):427-441. doi: 10.1080/17460441.2020.1703671. Epub 2020 Jan 3. Expert Opin Drug Discov. 2020. PMID: 31899983 Free PMC article. Review.
-
Induced pluripotent stem cell-based studies of Parkinson's disease: challenges and promises.CNS Neurol Disord Drug Targets. 2013 Dec;12(8):1114-27. CNS Neurol Disord Drug Targets. 2013. PMID: 24040813 Review.
-
Stemming the hype: what can we learn from iPSC models of Parkinson's disease and how can we learn it?J Parkinsons Dis. 2014;4(1):15-27. doi: 10.3233/JPD-130268. J Parkinsons Dis. 2014. PMID: 24398656 Review.
Cited by
-
Investigating the Therapeutics Effects of Oral Cavity Derived Stem Cells on Neurodegenerative Diseases: A Systematic Review.Basic Clin Neurosci. 2023 Sep-Oct;14(5):565-584. doi: 10.32598/bcn.2021.2892.1. Epub 2023 Sep 1. Basic Clin Neurosci. 2023. PMID: 38628839 Free PMC article. Review.
-
CRISPR/Cas9 facilitates genomic editing for large-scale functional studies in pluripotent stem cell cultures.Hum Genet. 2019 Dec;138(11-12):1217-1225. doi: 10.1007/s00439-019-02071-z. Epub 2019 Oct 12. Hum Genet. 2019. PMID: 31606751 Review.
-
Development of novel carbon-based biomedical platforms for intervention in xenotoxicant-induced Parkinson's disease onset.BMEmat. 2024 Dec;2(4):e12072. doi: 10.1002/bmm2.12072. Epub 2024 Jan 27. BMEmat. 2024. PMID: 40264898 Free PMC article.
-
Visualization Analysis of CRISPR Gene-editing Knowledge Map based on Citespace.Biol Bull Russ Acad Sci. 2021;48(6):705-720. doi: 10.1134/S1062359021060108. Epub 2021 Dec 17. Biol Bull Russ Acad Sci. 2021. PMID: 34955625 Free PMC article.
-
LUHMES Cells: Phenotype Refinement and Development of an MPP+-Based Test System for Screening Antiparkinsonian Drugs.Int J Mol Sci. 2023 Jan 1;24(1):733. doi: 10.3390/ijms24010733. Int J Mol Sci. 2023. PMID: 36614176 Free PMC article.
References
-
- Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373, 2055–2066. - PubMed
-
- Chang D, Nalls MA, Hallgrimsdottir IB, Hunkapiller J, van der Brug M, Cai F, International Parkinson’s Disease Genomics Consortium; 23andMe Research Team, Kerch-ner GA, Ayalon G, Bingol B, Sheng M, Hinds D, Behrens TW, Singleton AB, Bhangale TR, Graham RR (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat Genet 49, 1511–1516. - PMC - PubMed
-
- Foo JN, Tan LC, Irwan ID, Au WL, Low HQ, Prakash KM, Ahmad-Annuar A, Bei J, Chan AY, Chen CM, Chen YC, Chung SJ, Deng H, Lim SY, Mok V, Pang H, Pei Z, Peng R, Shang HF, Song K, Tan AH, Wu YR, Aung T, Cheng CY, Chew FT, Chew SH, Chong SA, Ebstein RP, Lee J, Saw SM, Seow A, Subramaniam M, Tai ES, Vithana EN, Wong TY, Heng KK, Meah WY, Khor CC, Liu H, Zhang F, Liu J, Tan EK (2017) Genome-wide association study of Parkinson’s disease in East Asians. Hum Mol Genet 26, 226–232. - PubMed
-
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839–840. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous